Generated by AI
Annexon Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target classical complement-driven inflammation in diseases of the body, brain, and eye. The company’s current pipeline includes investigational medicines for autoimmune, neurodegenerative, neuroimmune, and ophthalmic conditions, with programs designed to block C1q, the initiating molecule of the classical complement pathway. Its product candidates are being studied across areas such as Guillain-Barré syndrome, geographic atrophy, and other serious inflammatory disorders. Annexon’s work centers on complement biology, a mechanism involved in immune activation and tissue damage, giving the company a distinct position within precision immunotherapy research. Headquartered in Brisbane, California, Annexon serves the biotechnology and drug development market through clinical research, translational science, and late-stage therapeutic development.
Website1400 Sierra Point Parkway
Brisbane, CA, 94005
United States
The latest articles about ANNX.
2026-11-07. The following slide deck was published by Annexon, Inc.
Summary of Nov 16's posts. Generated by AI.
Summary of Nov 20's posts. Generated by AI.
BRISBANE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it will host a virtual investor event on Tuesday, November 3, 2026 at 11:00 AM ET regarding the ARCHER II Phase 3 program. To register, click here. Company management will highlight the Phase 3 ARCHER II clinical trial
Summary of Jun 5's posts. Generated by AI.
Investors talking about ANNX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.